Tacrolimus – Small Molecule, Giant Impact!
#TacrolimusAPI #Immunosuppressant #TransplantMedicine #AutoimmuneTreatment #GlobalPharma #APIExport #CerataPharmaceuticals #DermatologyAPI #CalcineurinInhibitor #PharmaBusiness #LifeSavingMedicines #WorldwideDistribution #GMPCompliant #B2BPharma #PharmaceuticalExcellence #ImmunologySupport #InnovationWithIntegrity
We supply GMP-grade Tacrolimus API under stringent quality standards for regulated and semi-regulated markets at Cerata Pharmaceuticals.
From milligram-sized samples to multi-kilo commercial bulk supplies. + our adaptable production system guarantees stability, scalability, and success for your formulation requirements.
* Tacrolimus is the cornerstone of standard immunosuppressive regimen after liver and kidney transplants in the USA, yet more than 15% of patients interchange because of side effects — creating a need for tailor-made formulations.
* Topical tacrolimus is increasingly being used in Germany and the Netherlands for vitiligo and atopic dermatitis, particularly where steroids are not effective.
* In India, Tacrolimus is becoming more used in combination regimens and generic products are on a roll in demand.
* While in South Africa, it is increasing its access through new national tender models for key immunosuppressants.
Off-label & New Uses — Beyond Transplants
✔ Lupus Nephritis
✔ Ulcerative Colitis (topical formulations)
✔ Severe Eczema & Vitiligo
✔ Refractory Uveitis
✔ Myasthenia Gravis
Leading trade snapshot:
+ India: Among leading global API exporters
+ USA: Biggest market for both systemic and topical tacrolimus
+ Brazil, Russia, China: Rapidly expanding generic demand
+ EU (Germany, France): High-purity premium demand for API
